0001209191-21-016880.txt : 20210303 0001209191-21-016880.hdr.sgml : 20210303 20210303163556 ACCESSION NUMBER: 0001209191-21-016880 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210301 FILED AS OF DATE: 20210303 DATE AS OF CHANGE: 20210303 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Parrish Jay CENTRAL INDEX KEY: 0001786372 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39083 FILM NUMBER: 21709557 MAIL ADDRESS: STREET 1: C/O VIR BIOTECHNOLOGY, INC. STREET 2: 499 ILLINOIS STREET, SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vir Biotechnology, Inc. CENTRAL INDEX KEY: 0001706431 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 812730369 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 415-906-4324 MAIL ADDRESS: STREET 1: 499 ILLINOIS STREET STREET 2: SUITE 500 CITY: SAN FRANCISCO STATE: CA ZIP: 94158 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-01 0 0001706431 Vir Biotechnology, Inc. VIR 0001786372 Parrish Jay C/O VIR BIOTECHNOLOGY, INC. 499 ILLINOIS STREET, SUITE 500 SAN FRANCISCO CA 94158 0 1 0 0 Chief Business Officer Common Stock 2021-03-01 4 M 0 4630 1.485 A 13890 D Common Stock 2021-03-01 4 M 0 2314 1.575 A 16204 D Common Stock 2021-03-01 4 S 0 6944 63.4405 D 9260 D Stock Option (Right to Buy) 1.485 2021-03-01 4 M 0 4630 0.00 D 2027-10-05 Common Stock 4630 9259 D Stock Option (Right to Buy) 1.575 2021-03-01 4 M 0 2314 0.00 D 2028-07-19 Common Stock 2314 39352 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on April 14, 2020. 1/4 of the shares subject to the stock option vested and became exercisable on April 3, 2018, and the remaining shares vest in 36 equal monthly installments thereafter. 1/4 of the shares subject to the stock option vested and became exercisable on July 19, 2019, and the remaining shares vest in 36 equal monthly installments thereafter. /s/ Howard Horn, Attorney-in-Fact 2021-03-03